Profound Medical (PROF) Stock Forecast, Price Target & Predictions
PROF Stock Forecast
Profound Medical stock forecast is as follows: an average price target of $14.25 (represents a 84.59% upside from PROF’s last price of $7.72) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
PROF Price Target
The average price target for Profound Medical (PROF) is $14.25 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $16.50 to $12.00. This represents a potential 84.59% upside from PROF's last price of $7.72.
PROF Analyst Ratings
According to 2 Wall Street analysts, Profound Medical's rating consensus is 'Buy'. The analyst rating breakdown for PROF stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Profound Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 23, 2024 | Ben Haynor | Lake Street | $16.50 | $10.28 | 60.47% | 113.73% |
| Jul 15, 2024 | Rick Wise | Stifel Nicolaus | $12.00 | $9.15 | 31.15% | 55.44% |
The latest Profound Medical stock forecast, released on Jul 23, 2024 by Ben Haynor from Lake Street, set a price target of $16.50, which represents a 60.47% increase from the stock price at the time of the forecast ($10.28), and a 113.73% increase from PROF last price ($7.72).
Profound Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 2 |
| Avg Price Target | - | $14.25 | $14.25 |
| Last Closing Price | $7.72 | $7.72 | $7.72 |
| Upside/Downside | -100.00% | 84.59% | 84.59% |
In the current month, the average price target of Profound Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Profound Medical's last price of $7.72. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 06, 2023 | Lake Street | Buy | Buy | Hold |
| Feb 22, 2022 | Raymond James | - | Outperform | Downgrade |
Profound Medical's last stock rating was published by Lake Street on Jan 06, 2023. The company gave PROF a "Buy" rating, the same as its previous rate.
Profound Medical Financial Forecast
Profound Medical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.86M | $1.26M | $2.04M | $2.02M | $1.36M | $998.00K | $2.54M | $2.63M | $711.00K | $2.85M | $2.23M | $1.04M | $1.10M | $2.17M | $515.35K |
| Avg Forecast | $24.30M | $21.90M | $19.60M | $17.40M | $9.70M | $7.90M | $6.47M | $5.80M | $4.04M | $3.05M | $2.64M | $2.44M | $1.97M | $2.20M | $2.13M | $2.12M | $2.67M | $2.41M | $2.02M | $1.76M | $2.79M | $3.57M | $2.20M | $2.48M | $2.31M | $1.71M | $737.22K | $892.29K | $2.08M | $1.16M |
| High Forecast | $27.98M | $25.21M | $22.57M | $20.03M | $11.17M | $9.10M | $7.45M | $6.68M | $4.65M | $3.27M | $3.04M | $2.81M | $2.27M | $2.53M | $2.46M | $2.44M | $3.08M | $2.78M | $2.02M | $1.97M | $3.13M | $4.01M | $2.47M | $2.78M | $2.59M | $1.92M | $827.38K | $1.00M | $2.34M | $1.30M |
| Low Forecast | $19.18M | $17.29M | $15.47M | $13.74M | $7.66M | $6.24M | $5.11M | $4.58M | $3.19M | $2.90M | $2.08M | $1.93M | $1.56M | $1.74M | $1.68M | $1.67M | $2.11M | $1.91M | $2.02M | $1.62M | $2.57M | $3.29M | $2.03M | $2.28M | $2.13M | $1.58M | $679.72K | $822.70K | $1.92M | $1.07M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | - | 1 | 2 | 2 | 1 | 11 | 16 | 9 | 11 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.88% | 0.47% | 0.84% | 1.00% | 0.78% | 0.36% | 0.71% | 1.20% | 0.29% | 1.24% | 1.30% | 1.41% | 1.23% | 1.04% | 0.44% |
Profound Medical's average Quarter revenue forecast for Jun 23 based on 4 analysts is $2.13M, with a low forecast of $1.68M, and a high forecast of $2.46M. PROF's average Quarter revenue forecast represents a 14.69% increase compared to the company's last Quarter revenue of $1.86M (Mar 23).
Profound Medical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | - | 1 | 2 | 2 | 1 | 11 | 16 | 9 | 11 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-6.22M | $-5.52M | $-7.61M | $-7.04M | $-6.74M | $-10.05M | $-5.43M | $-6.49M | $-7.03M | $-7.35M | $-5.47M | $-4.82M | $-1.63M | $-3.35M | $-4.08M |
| Avg Forecast | $-24.30M | $-21.90M | $-19.60M | $-17.40M | $-9.70M | $-7.90M | $-6.47M | $-5.80M | $-4.04M | $-3.05M | $-2.64M | $-2.44M | $-1.97M | $-2.20M | $-2.13M | $-2.12M | $-2.67M | $-5.29M | $-2.02M | $-8.23M | $-2.79M | $-4.81M | $-4.24M | $-4.42M | $-2.31M | $-4.22M | $-2.74M | $-2.02M | $-2.08M | $-3.51M |
| High Forecast | $-19.18M | $-17.29M | $-15.47M | $-13.74M | $-7.66M | $-6.24M | $-5.11M | $-4.58M | $-3.19M | $-2.90M | $-2.08M | $-1.93M | $-1.56M | $-1.74M | $-1.68M | $-1.67M | $-2.11M | $-4.23M | $-2.02M | $-6.58M | $-2.57M | $-3.85M | $-3.40M | $-3.54M | $-2.13M | $-3.38M | $-2.19M | $-1.62M | $-1.92M | $-2.81M |
| Low Forecast | $-27.98M | $-25.21M | $-22.57M | $-20.03M | $-11.17M | $-9.10M | $-7.45M | $-6.68M | $-4.65M | $-3.27M | $-3.04M | $-2.81M | $-2.27M | $-2.53M | $-2.46M | $-2.44M | $-3.08M | $-6.35M | $-2.02M | $-9.87M | $-3.13M | $-5.77M | $-5.09M | $-5.31M | $-2.59M | $-5.07M | $-3.29M | $-2.43M | $-2.34M | $-4.21M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.94% | 2.06% | 1.44% | 3.49% | 0.82% | 3.60% | 1.13% | 1.53% | 1.59% | 3.18% | 1.30% | 1.76% | 0.80% | 1.61% | 1.16% |
undefined analysts predict PROF's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Profound Medical's previous annual EBITDA (undefined) of $NaN.
Profound Medical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | - | 1 | 2 | 2 | 1 | 11 | 16 | 9 | 11 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-6.74M | $-9.53M | $-5.00M | $-5.93M | $-8.21M | $-10.16M | $-6.00M | $-7.04M | $-7.50M | $-7.36M | $-6.08M | $-5.38M | $-2.54M | $-4.10M | $-4.74M |
| Avg Forecast | - | - | - | - | $-6.20M | $-6.42M | $-6.63M | $-7.94M | $-10.11M | $-9.92M | $-9.41M | $-9.87M | $-10.12M | $-11.21M | $-11.37M | $-11.68M | $-12.24M | $-5.83M | $-12.40M | $-8.79M | $-9.67M | $-5.30M | $-4.61M | $-4.72M | $-8.15M | $-4.69M | $-3.05M | $-3.16M | $-12.56M | $-4.07M |
| High Forecast | - | - | - | - | $-4.50M | $-4.66M | $-4.82M | $-5.77M | $-7.35M | $-8.96M | $-6.84M | $-7.17M | $-8.31M | $-8.14M | $-8.26M | $-8.48M | $-8.89M | $-4.67M | $-12.40M | $-7.03M | $-8.69M | $-4.24M | $-3.68M | $-3.78M | $-7.32M | $-3.75M | $-2.44M | $-2.53M | $-11.29M | $-3.26M |
| Low Forecast | - | - | - | - | $-7.42M | $-7.68M | $-7.94M | $-9.50M | $-12.10M | $-11.20M | $-11.27M | $-11.81M | $-11.57M | $-13.41M | $-13.61M | $-13.98M | $-14.65M | $-7.00M | $-12.40M | $-10.55M | $-11.21M | $-6.36M | $-5.53M | $-5.67M | $-9.45M | $-5.63M | $-3.67M | $-3.79M | $-14.56M | $-4.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.58% | 0.78% | 0.86% | 0.48% | 0.93% | 1.05% | 1.13% | 1.53% | 1.59% | 0.90% | 1.30% | 1.76% | 0.80% | 0.33% | 1.16% |
Profound Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PROF's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Profound Medical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | - | 1 | 2 | 2 | 1 | 11 | 16 | 9 | 11 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.21M | $3.77M | $4.59M | $5.03M | $4.55M | $5.53M | $4.54M | $4.18M | $3.72M | $3.45M | $3.03M | $2.67M | $3.04M | $2.99M | $2.21M |
| Avg Forecast | $55.79M | $50.28M | $45.00M | $39.95M | $22.27M | $18.14M | $14.85M | $13.32M | $9.28M | $7.01M | $6.06M | $5.60M | $4.52M | $5.05M | $4.90M | $4.86M | $6.14M | $5.54M | $4.63M | $4.03M | $6.40M | $8.19M | $5.04M | $2.34M | $5.30M | $3.93M | $1.69M | $2.05M | $4.78M | $2.67M |
| High Forecast | $64.23M | $57.89M | $51.81M | $45.99M | $25.64M | $20.88M | $17.09M | $15.33M | $10.68M | $7.51M | $6.98M | $6.45M | $5.21M | $5.81M | $5.64M | $5.60M | $7.07M | $6.38M | $4.63M | $4.53M | $7.19M | $9.20M | $5.66M | $2.81M | $5.94M | $4.41M | $1.90M | $2.30M | $5.37M | $2.99M |
| Low Forecast | $44.05M | $39.70M | $35.53M | $31.54M | $17.58M | $14.32M | $11.72M | $10.51M | $7.32M | $6.65M | $4.79M | $4.42M | $3.57M | $3.99M | $3.87M | $3.84M | $4.84M | $4.38M | $4.63M | $3.72M | $5.91M | $7.56M | $4.65M | $1.87M | $4.88M | $3.62M | $1.56M | $1.89M | $4.41M | $2.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.87% | 0.61% | 0.83% | 1.09% | 1.13% | 0.86% | 0.55% | 0.83% | 1.59% | 0.65% | 0.77% | 1.58% | 1.48% | 0.62% | 0.83% |
Profound Medical's average Quarter SG&A projection for Jun 23 is $4.90M, based on 4 Wall Street analysts, with a range of $3.87M to $5.64M. The forecast indicates a 16.31% rise compared to PROF last annual SG&A of $4.21M (Mar 23).
Profound Medical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | - | 1 | 2 | 2 | 1 | 11 | 16 | 9 | 11 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.32 | $-0.46 | $-0.24 | $-0.29 | $-0.40 | $-0.50 | $-0.29 | $-0.35 | $-0.37 | $-0.39 | $-0.32 | $-0.34 | $-0.18 | $-0.28 | $-0.43 |
| Avg Forecast | - | - | - | - | $-0.25 | $-0.26 | $-0.27 | $-0.32 | $-0.41 | $-0.41 | $-0.39 | $-0.40 | $-0.41 | $-0.46 | $-0.47 | $-0.48 | $-0.50 | $-0.52 | $-0.51 | $-0.56 | $-0.45 | $-0.37 | $-0.36 | $-0.34 | $-0.38 | $-0.33 | $-0.31 | $-0.38 | $-0.59 | $-0.49 |
| High Forecast | - | - | - | - | $-0.18 | $-0.19 | $-0.20 | $-0.24 | $-0.30 | $-0.37 | $-0.28 | $-0.29 | $-0.34 | $-0.33 | $-0.34 | $-0.35 | $-0.36 | $-0.38 | $-0.51 | $-0.50 | $-0.41 | $-0.33 | $-0.33 | $-0.31 | $-0.34 | $-0.29 | $-0.28 | $-0.34 | $-0.53 | $-0.44 |
| Low Forecast | - | - | - | - | $-0.30 | $-0.31 | $-0.32 | $-0.39 | $-0.50 | $-0.46 | $-0.46 | $-0.48 | $-0.47 | $-0.55 | $-0.56 | $-0.57 | $-0.60 | $-0.62 | $-0.51 | $-0.65 | $-0.52 | $-0.43 | $-0.42 | $-0.40 | $-0.44 | $-0.38 | $-0.36 | $-0.44 | $-0.68 | $-0.57 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.67% | 0.92% | 0.46% | 0.57% | 0.72% | 1.11% | 0.79% | 0.96% | 1.07% | 1.03% | 0.99% | 1.09% | 0.47% | 0.48% | 0.87% |
According to undefined Wall Street analysts, Profound Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PROF previous annual EPS of $NaN (undefined).
Profound Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NVRO | Nevro | $5.79 | $32.99 | 469.78% | Hold |
| CVRX | CVRx | $7.85 | $15.83 | 101.66% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| PROF | Profound Medical | $7.72 | $14.25 | 84.59% | Buy |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| FNA | Paragon 28 | $7.39 | $11.50 | 55.62% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| LIVN | LivaNova | $48.53 | $71.25 | 46.82% | Buy |
| SIBN | SI-BONE | $15.73 | $20.00 | 27.15% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| IRMD | IRadimed | $48.47 | $60.00 | 23.79% | Buy |
| AORT | Artivion | $25.25 | $30.00 | 18.81% | Buy |
| ITGR | Integer | $126.78 | $131.00 | 3.33% | Buy |
| SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
PROF Forecast FAQ
Is Profound Medical a good buy?
Yes, according to 2 Wall Street analysts, Profound Medical (PROF) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of PROF's total ratings.
What is PROF's price target?
Profound Medical (PROF) average price target is $14.25 with a range of $12 to $16.5, implying a 84.59% from its last price of $7.72. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Profound Medical stock go up soon?
According to Wall Street analysts' prediction for PROF stock, the company can go up by 84.59% (from the last price of $7.72 to the average price target of $14.25), up by 113.73% based on the highest stock price target, and up by 55.44% based on the lowest stock price target.
Can Profound Medical stock reach $12?
PROF's average twelve months analyst stock price target of $14.25 supports the claim that Profound Medical can reach $12 in the near future.
What are Profound Medical's analysts' financial forecasts?
Profound Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $29.87M (high $34.39M, low $23.58M), average EBITDA is $-29.867M (high $-23.579M, low $-34.386M), average net income is $-27.187M (high $-19.746M, low $-32.535M), average SG&A $68.57M (high $78.95M, low $54.14M), and average EPS is $-1.112 (high $-0.808, low $-1.331). PROF's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $83.2M (high $95.79M, low $65.68M), average EBITDA is $-83.2M (high $-65.684M, low $-95.789M), average net income is $0 (high $0, low $0), average SG&A $191.02M (high $219.93M, low $150.81M), and average EPS is $0 (high $0, low $0).
Did the PROF's actual financial results beat the analysts' financial forecasts?
Based on Profound Medical's last annual report (Dec 2022), the company's revenue was $6.68M, which missed the average analysts forecast of $8.86M by -24.58%. Apple's EBITDA was $-25.474M, beating the average prediction of $-18.203M by 39.95%. The company's net income was $-28.669M, missing the average estimation of $-39.263M by -26.98%. Apple's SG&A was $17.93M, missing the average forecast of $20.34M by -11.83%. Lastly, the company's EPS was $-1.4, missing the average prediction of $-2.09 by -33.01%. In terms of the last quarterly report (Mar 2023), Profound Medical's revenue was $1.86M, missing the average analysts' forecast of $2.12M by -12.13%. The company's EBITDA was $-6.219M, beating the average prediction of $-2.117M by 193.81%. Profound Medical's net income was $-6.741M, missing the average estimation of $-11.68M by -42.29%. The company's SG&A was $4.21M, missing the average forecast of $4.86M by -13.35%. Lastly, the company's EPS was $-0.32, missing the average prediction of $-0.478 by -33.04%